MNPR
Closed
Monopar Therapeutics Inc
33.56
-2.22 (-6.20%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 35.78
Day's Range: 33. - 36.195
Send
sign up or login to leave a comment!
When Written:
1.26
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois, USA, and was founded in 2014. Monopar's lead product candidate, Validive, is a late-stage clinical asset that is being developed as a treatment for severe oral mucositis, a common side effect of radiation therapy and chemotherapy. The company is also developing a pipeline of novel therapies that target multiple cancer indications, including ovarian, lung, and breast cancer. Monopar's approach to drug development is based on identifying therapeutic targets that are specific to cancer cells and developing drugs that can selectively target those cells while minimizing damage to healthy cells. The company is committed to advancing its pipeline of cancer therapies through rigorous clinical testing and regulatory approval processes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








